GlassScriptPhysician profile
Maria Hirsch
NPI 1659892644
$7,357.81
in general payments reported to CMS, 2019-2025
35 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $424 · 2023: $842 · 2024: $3,429 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,989 · Travel and Lodging: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,989.00 |
| Travel and Lodging | $944.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,243.30 | 2024-2025 | Infinity |
| Medtronic, INC. | $694.30 | 2022-2023 | Corevalve Evolut R |
| Abbvie INC. | $589.51 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $389.93 | 2023-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $315.34 | 2024-2025 | Rystiggo, Nayzilam, Briviact |
| Alexion Pharmaceuticals, INC. | $300.96 | 2024-2025 | Ultomiris |
| Merz Pharmaceuticals, LLC | $300.88 | 2023-2025 | Xeomin, Inbrija |
| Tg Therapeutics, INC. | $294.97 | 2024-2025 | |
| Eisai INC. | $291.13 | 2024-2025 | |
| Argenx US, INC. | $281.09 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $258.32 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $255.42 | 2024-2025 | Austedo Xr, Austedo Xr |
| Medical Device Business Services, INC. | $222.45 | 2022 | |
| Lundbeck LLC | $219.32 | 2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $189.33 | 2023-2025 | Emgality, Kisunla, Reyvow |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $176.90 | 2022 | |
| Biogen, INC. | $147.86 | 2023-2025 | Spinraza, Leqembi, Qalsody |
| Pfizer INC. | $139.86 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $122.60 | 2024-2025 | Crexont, Ongentys 50mg Capsules 30, Rytary |
| Averitas Pharma INC. | $101.70 | 2024-2025 | Qutenza |
| Amgen INC. | $101.60 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $94.98 | 2023-2025 | |
| Sk Life Science, INC. | $84.00 | 2024-2025 | |
| Genentech USA, INC. | $79.19 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.13 | 2025 | Lifevest |
| Vanda Pharmaceuticals INC. | $71.18 | 2024-2025 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $58.27 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $51.35 | 2024 | Hyqvia |
| Jazz Pharmaceuticals INC. | $37.30 | 2024 | |
| Boston Scientific Corporation | $35.74 | 2025 | General - Dbs |
| Csl Behring | $32.58 | 2025 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $31.55 | 2025 | Wainua |
| Janssen Biotech, INC. | $26.35 | 2025 | |
| Ns Pharma, INC. | $22.15 | 2025 | Viltepso |
| Mdd US Operations, LLC | $18.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.